Keytruda Six Week Dosing Schedule

That just took the wind out of O & Y!

 

6 week dosing versus 4 week dosing took the wind out of a superior efficacy combination? Mono to Mono, some patients might prefer Q6, but I bet facilities want that Q4 billing for infusion.

Are you fucking high?

 

Q6 is superior to Q4 when patients want to minimize exposure to hospitals. Also frees up more infusion chairs.

 

Superior efficacy? Who is high now?

Billing 4 week vs. 6 week to limit patient flow during a pandemic?

Best in Industry? Go back to sleep !

 

In *every* indication where both pembro and O+Y is approved, O+Y is superior. Try learning to read next time.

The pandemic won't last forever, Merck lucked out with a ridiculous review time on submission of PK modeling data.

 

Go convince an oncologist that you’re right. Because the sales data says you’re wrong.

 

Thanks Marty. Go back to drinking that delicious red fruit drink that Amit poured you.

 

Already eating what is left of our tiny market share.

Later chumps!

 

Bye Community Reps.....what a waste of money

 

No, it doesn't. Compare indication to indication where pembro mono vs O+Y is approved, and O+Y is vastly superior. If you lack the brain cells to go into that level and just compare total pembro versus O+Y, I don't know what to tell you. It's not a secret that pembro sells more, but that isn't the discuss here.

Stupid fuckin reps.

 

how about 1L NSCLC?

 

O&Y ain’t cutting it in 1L NSCLC. Sales are not meeting expectations.

Signed,

Amit the nit-wit

 

Do you have weekly sales data somewhere that no one else has?

 

No my point was in regards to the comment that nivo/ipi is vastly superior to pembro in all approver indications in which the data from the studies indicates differently. Not talking sales figures at all.

 

Sounds like a 'Karen' from Oncology that does cross comparison of trials and is still wrong!

 

You guys cannot even penetrate jello with your index finger. How the hell are you going to beat Keytruda and penetrate a health care system?

Smoke some more dope!

 

Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer To Stop for Futility and Patients to Discontinue... - Merck.com

Why to go f-tards!

 

Merck is hated by the oncology community, yet sells billions more per year than Opdivo. (And look at projected sales). What does that say about BMS/Opdivo. I left when Opdivo was still king. How long can you stay playing second fiddle until off patent? Make sure you get/fake your contacts this week. . Make your metrics.

 

Those metrics aren’t going to cover you for long....better start looking for a job